CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Value Pricing Subsidiesbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02271269
NCT02271269N/ACompleted

A Randomized Controlled Trial to Increase Glaucoma Medication Adherence Using Value Pricing

Duke-NUS Graduate Medical School·interventional·Posted Oct 22, 2014·Updated May 1, 2017

In Brief

A clinical study evaluating Value Pricing Subsidies for Glaucoma. Completed, enrolled 100 participants across 1 site.

Detailed Summary

Glaucoma topical eye medications, when adhered to, are effective at controlling disease progression. Yet evidence shows that many glaucoma patients have incomplete adherence to medications, with disease progression resulting in significant costs to the patient and health system. Through the approach of value pricing, a link can be made between non-adherence and its resulting costs by granting subsidies to adherent patients for their medications and physician visits. This 6-month randomized controlled trial among 100 glaucoma patients from the Singapore National Eye Centre aims to test the extent to which value pricing can improve medication adherence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesSingapore

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 22, 2014
Enrollment StartNov 1, 2014
Primary CompletionJan 1, 2017
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.7 years ago

Interventions

Value Pricing Subsidiesbehavioral

* Usual care for glaucoma * Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed. * Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points.